世界の線維筋痛症市場規模、シェア、トレンド分析レポート – 業界概要と2033年までの予測

線維筋痛症市場規模

• 世界の線維筋痛症市場規模は、2025年には27億5000万米ドルと評価され、予測期間中の年平均成長率（CAGR）7.00%で、2033年には47億2000万米ドル に達すると予測されている 。
• 市場の成長は、線維筋痛症の罹患率の上昇、慢性疼痛疾患に対する意識の高まり、診断率の向上によって大きく促進されています。薬物療法や認知行動療法、理学療法などの非薬物療法を含む治療アプローチの進歩も、市場拡大をさらに後押ししています。
• さらに、効果的で患者中心の長期的な管理ソ​​リューションに対する需要の高まりにより、線維筋痛症治療は現代の疼痛管理および神経科医療の不可欠な要素として確立されつつあります。これらの要因が複合的に作用することで、線維筋痛症治療ソリューションの普及が加速し、世界の線維筋痛症市場の成長を大きく促進しています。

線維筋痛症市場分析

• 線維筋痛症の慢性かつ複雑な性質のため、薬物療法（抗うつ薬、抗けいれん薬、鎮痛薬など）や理学療法、認知行動療法などの非薬物療法を含む線維筋痛症の治療法は、現代医療においてますます重要になっています。この疾患に対する認識の高まりと診断基準の改善が、より広範な治療の普及を後押ししています。
• 線維筋痛症に対する需要の高まりは、主に慢性疼痛疾患の有病率の増加、患者と医療従事者の意識向上、そして長期的な疾患管理による生活の質の向上への重視の高まりによって促進されています。これらの要因が、包括的かつ学際的な治療アプローチの採用を促しています。
• 北米は線維筋痛症市場を牽引しており、2025年には世界収益の約45%を占める見込みである。これは、高い診断率、強固な医療インフラ、そして承認された治療法の普及に支えられている。米国は、この地域における最大の貢献国であり続ける。
• アジア太平洋地域は、予測期間中、線維筋痛症市場において最も急速に成長する地域になると予想されており、慢性疼痛疾患に対する認識の高まり、医療へのアクセスの改善、医療費の増加が、予測される年平均成長率（CAGR）を牽引する要因となる。
• 経口薬セグメントは、投与の容易さ、高い患者コンプライアンス、および長期症状管理における経口薬の広範な使用を背景に、2025年には市場収益の48.3%という最大のシェアを占めた。

レポートの範囲と線維筋痛症市場のセグメンテーション

線維筋痛症市場の動向

「多角的疼痛管理と個別化治療の進歩」

• 世界の線維筋痛症市場における重要かつ加速的なトレンドは、薬物療法、理学療法、行動療法を組み合わせた多角的疼痛管理アプローチへの移行が進んでいることである。この統合的なアプローチは、患者の治療効果と生活の質を全体的に向上させている。
• 例えば、医療従事者は、症状をより効果的に管理するために、抗うつ薬、抗けいれん薬、認知行動療法（CBT）などの併用療法をますます採用しており、これは個別化された治療戦略への移行を反映している。
• 医薬品開発の進歩により、慢性疼痛、疲労、睡眠障害などの特定の症状に対処する標的療法が可能になっている。新しい製剤や徐放性製剤は、治療遵守率と患者の快適性を向上させている。
• モバイルヘルスアプリケーションや遠隔モニタリングシステムなどのデジタルヘルスツールの統合は、継続的な患者管理を支援し、症状の進行状況や治療反応のより良い追跡を可能にしている。
• こうした個別化医療や患者中心医療への傾向は治療プロトコルを再構築しており、製薬会社や医療提供者は個々の患者のプロファイルに基づいたオーダーメイドの治療法に注力している。
• 線維筋痛症とその日常生活への影響に対する認識が高まり続けるにつれ、先進国市場と新興国市場の両方で、包括的かつ長期的な管理ソ​​リューションへの需要が高まっている。

線維筋痛症市場の動向

ドライバ

「慢性疼痛疾患の有病率の上昇と認知度の高まり」

• 線維筋痛症を含む慢性疼痛疾患の有病率の上昇は市場成長の大きな原動力となっており、診断と長期治療を求める患者数が増加している。
• 例えば、保健機関や患者擁護団体による啓発キャンペーンの強化により、特に先進地域では診断率が向上し、早期治療開始が促進されている。
• 線維筋痛症が正当な医学的疾患としてより広く認識されるようになったことで、医療機関への受診が増加し、効果的な治療法への需要が高まっている。
• さらに、診断基準の改善と医師の教育の向上により、この疾患のより早期かつ正確な特定が可能になっている。
• 高齢者人口の増加は、慢性疼痛疾患にかかりやすいことから、線維筋痛症治療の需要増加の一因となっている。
• 医療費の増加と疼痛管理サービスへのアクセス向上は、世界的な市場拡大をさらに後押ししている。

抑制／挑戦

「治療効果の限定性と長期管理の高コスト」

• 線維筋痛症市場における主要な課題の一つは、利用可能な治療法の有効性が限られていることである。ほとんどの治療法は、病気を治すのではなく、症状の管理に重点を置いているためだ。
• For instance, commonly prescribed drugs such as pregabalin and duloxetine may not provide adequate relief for all patients and can be associated with side effects, leading to discontinuation or reduced adherence
• The chronic nature of fibromyalgia requires long-term treatment and continuous management, which can result in significant financial burden for patients
• In addition, lack of standardized treatment protocols and variability in patient response complicate disease management
• Insurance coverage limitations and reimbursement challenges in certain regions further restrict access to advanced therapies
• Addressing these challenges will require continued research into more effective therapies, improved clinical guidelines, and increased accessibility to affordable treatment options

Fibromyalgia Market Scope

The market is segmented on the basis of diagnosis, treatment, route of administration, end-users, and distribution channel.

• By Type

On the basis of type, the Fibromyalgia market is segmented into blood tests and others. The blood tests segment dominated the largest market revenue share of 46.2% in 2025, driven by increasing use of laboratory testing to rule out other conditions and support differential diagnosis of fibromyalgia. Hospitals and specialty clinics frequently rely on blood tests to identify underlying issues such as autoimmune disorders or inflammation markers. Physicians prefer blood tests as part of initial diagnostic evaluation. Growing awareness about early diagnosis supports adoption. Integration with advanced diagnostic technologies improves accuracy. High patient inflow in hospitals contributes to segment growth. Insurance coverage for diagnostic procedures enhances accessibility. Continuous advancements in lab testing techniques strengthen reliability. Clinical guidelines support use of blood tests in evaluation. Research initiatives improve diagnostic pathways. Increasing prevalence of chronic pain conditions drives demand.

The others segment is expected to witness the fastest CAGR of 9.4% from 2026 to 2033, fueled by rising adoption of clinical examination, symptom-based diagnosis, and emerging diagnostic tools. Physicians increasingly rely on comprehensive assessment methods beyond lab tests. Growing awareness about fibromyalgia improves early diagnosis rates. Specialty clinics adopt multidisciplinary diagnostic approaches. Technological advancements support improved screening tools. Emerging markets show rising diagnostic capabilities. Patient education programs enhance recognition of symptoms. Integration with digital health tools improves assessment accuracy. Increasing focus on personalized diagnosis drives adoption. Clinical research supports development of new diagnostic techniques. Healthcare providers emphasize holistic evaluation methods.

• By Treatment

On the basis of treatment, the Fibromyalgia market is segmented into medication, therapy, and others. The medication segment dominated the largest market revenue share of 42.7% in 2025, driven by widespread use of pain relievers, antidepressants, and anticonvulsants for symptom management. Hospitals and specialty clinics frequently prescribe medications to manage chronic pain and fatigue. High patient dependence on pharmacological treatment supports dominance. Physician familiarity and established treatment guidelines reinforce adoption. Availability of multiple drug classes enhances flexibility. Insurance coverage improves accessibility. Pharmaceutical advancements improve efficacy and tolerability. Patient adherence remains relatively high. Awareness programs support treatment continuation. Integration with combination therapies enhances outcomes. Growing prevalence of fibromyalgia drives demand.

The therapy segment is expected to witness the fastest CAGR of 10.8% from 2026 to 2033, fueled by increasing adoption of non-pharmacological treatments such as cognitive behavioral therapy, physical therapy, and lifestyle management. Patients prefer holistic approaches with fewer side effects. Specialty clinics expand therapy-based treatment programs. Growing awareness of mental health supports adoption. Integration with digital therapy platforms enhances accessibility. Emerging markets show rising acceptance of therapy options. Healthcare providers emphasize multidisciplinary care. Research supports effectiveness of non-drug interventions. Patient education improves engagement. Telehealth services facilitate therapy sessions. Long-term benefits drive sustained growth.

• By Route of Administration

On the basis of route of administration, the Fibromyalgia market is segmented into oral, parenteral, and others. The oral segment dominated the largest market revenue share of 48.3% in 2025, driven by ease of administration, high patient compliance, and widespread use of oral medications for long-term symptom management. Patients prefer oral drugs due to convenience and accessibility. Homecare settings strongly support oral therapy adoption. Pharmaceutical companies focus on oral formulations. Cost-effectiveness enhances affordability. Physician preference supports continued usage. Integration with chronic disease management programs strengthens demand. Awareness initiatives encourage adherence. Emerging markets show strong uptake. Availability of generic drugs further boosts adoption.

The parenteral segment is expected to witness the fastest CAGR of 8.6% from 2026 to 2033, fueled by increasing use in severe cases requiring rapid symptom relief and controlled dosing. Hospitals and specialty centres prefer parenteral administration in acute scenarios. Clinical protocols support its use in specific conditions. Technological advancements improve delivery systems. Patient monitoring enhances safety. Growing healthcare infrastructure supports adoption. Research initiatives explore advanced formulations. Integration with hospital-based care strengthens demand. Emerging markets show gradual uptake. Increasing focus on effective pain management drives growth.

• By End-Users

On the basis of end-users, the Fibromyalgia market is segmented into hospitals, homecare, specialty clinics, and others. The hospitals segment dominated the largest market revenue share of 47.9% in 2025, driven by availability of multidisciplinary care, diagnostic facilities, and access to pharmacological treatments. Hospitals manage complex fibromyalgia cases effectively. High patient inflow supports dominance. Access to advanced diagnostic tools improves evaluation. Physician expertise enhances treatment outcomes. Insurance coverage facilitates hospital-based care. Government healthcare initiatives support infrastructure. Integration with pain management programs strengthens adoption. Research and clinical studies reinforce hospital role. Patient trust drives preference.

The homecare segment is expected to witness the fastest CAGR of 11.2% from 2026 to 2033, fueled by increasing preference for long-term management at home and growing use of telehealth services. Patients opt for homecare for convenience and comfort. Remote monitoring tools support treatment adherence. Cost-effectiveness drives adoption. Emerging markets show rising homecare services. Awareness programs improve patient engagement. Integration with digital health platforms enhances accessibility. Healthcare providers expand homecare offerings. Supportive therapies strengthen outcomes. Convenience and flexibility accelerate growth.

• By Distribution Channel

On the basis of distribution channel, the Fibromyalgia market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment dominated the largest market revenue share of 45.1% in 2025, driven by direct linkage with hospital treatment protocols and availability of prescribed medications. Hospitals ensure immediate access to drugs for patients. Physician prescriptions are primarily fulfilled through hospital pharmacies. Regulatory compliance ensures safety and quality. Strong supply chain supports availability. Insurance coverage improves access. Patient trust reinforces dominance. Integration with hospital systems enhances efficiency.

The online pharmacy segment is expected to witness the fastest CAGR of 12.7% from 2026 to 2033, driven by increasing digital adoption, convenience, and availability of medications through e-commerce platforms. Patients prefer doorstep delivery for long-term therapy. Smartphone penetration supports online purchases. Telemedicine integration enhances prescription access. Competitive pricing attracts consumers. Awareness of online platforms is increasing. Emerging markets show rapid adoption. Accessibility and convenience sustain growth. Expansion of digital healthcare ecosystems further accelerates demand.

Fibromyalgia Market Regional Analysis

• North America dominated the fibromyalgia market, accounting for approximately 45% of global revenue in 2025, supported by high diagnosis rates, strong healthcare infrastructure, and widespread availability of approved therapies
• The region benefits from increased awareness of chronic pain disorders and access to specialized pain management services
• The Fibromyalgia market represents the largest share within North America, driven by advanced diagnostic capabilities, high healthcare expenditure, and strong adoption of pharmacological and non-pharmacological treatment approaches. The presence of key pharmaceutical companies and ongoing research initiatives further supports market growth

U.S. Fibromyalgia Market Insight

The U.S. fibromyalgia market captured the largest revenue share within North America, driven by increasing prevalence of chronic pain conditions and strong awareness regarding early diagnosis and treatment. The country benefits from a well-established healthcare system, widespread availability of approved medications, and increasing use of multidisciplinary treatment approaches, including physical therapy and behavioral interventions. In addition, favorable reimbursement policies and continuous advancements in pain management therapies are contributing to market expansion.

Europe Fibromyalgia Market Insight

The Europe fibromyalgia market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by increasing awareness of fibromyalgia, improved diagnostic practices, and growing adoption of multidisciplinary treatment approaches. The presence of supportive healthcare systems and rising healthcare expenditure are further contributing to market growth across the region.

U.K. Fibromyalgia Market Insight

The U.K. fibromyalgia market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing recognition of chronic pain disorders and improved access to healthcare services. Government initiatives and growing awareness among healthcare professionals are supporting early diagnosis and effective disease management.

Germany Fibromyalgia Market Insight

The Germany fibromyalgia market is expected to expand at a considerable CAGR during the forecast period, fueled by advanced healthcare infrastructure, strong focus on clinical research, and increasing demand for effective pain management therapies. Germany’s emphasis on innovation and patient care is promoting the adoption of comprehensive treatment approaches.

Asia-Pacific Fibromyalgia Market Insight

The Asia-Pacific fibromyalgia market is expected to be the fastest-growing region during the forecast period, driven by increasing awareness of chronic pain conditions, improving healthcare access, and rising healthcare expenditure. Large patient populations and expanding healthcare infrastructure in countries such as China, India, and Japan are significantly contributing to market growth.

Japan Fibromyalgia Market Insight

The Japan fibromyalgia market is gaining momentum due to growing awareness of fibromyalgia, improving diagnostic capabilities, and increasing focus on pain management. The country’s aging population further contributes to rising demand for effective treatment solutions.

China Fibromyalgia Market Insight

The China fibromyalgia market accounted for a significant revenue share in Asia Pacific, driven by expanding healthcare infrastructure, rising healthcare expenditure, and increasing awareness of chronic pain disorders. Government initiatives to improve healthcare access and the growing availability of treatment options are key factors propelling market growth in the country.

Fibromyalgia Market Share

The Fibromyalgia industry is primarily led by well-established companies, including:

• Pfizer (U.S.)
• Eli Lilly and Company (U.S.)
• Johnson & Johnson (U.S.)
• AbbVie (U.S.)
• Novartis (Switzerland)
• GlaxoSmithKline (U.K.)
• Sanofi (France)
• Bayer (Germany)
• Merck & Co. (U.S.)
• Teva Pharmaceutical (Israel)
• Sun Pharma (India)
• Dr. Reddy’s Laboratories (India)
• Cipla (India)
• Lupin Pharmaceuticals (India)
• Amgen (U.S.)
• AstraZeneca (U.K.)
• Takeda Pharmaceutical (Japan)
• Bristol-Myers Squibb (U.S.)
• Endo International (Ireland)
• Hoffmann-La Roche (Switzerland)

Latest Developments in Global Fibromyalgia Market

• In April 2022, Tonix Pharmaceuticals initiated the Phase 3 RESILIENT clinical trial of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia, marking a significant late-stage development aimed at introducing the first new therapy in over a decade
• In December 2023, Tonix Pharmaceuticals announced positive topline results from its Phase 3 RESILIENT trial, demonstrating statistically significant reductions in daily pain and improvements in sleep quality and fatigue in fibromyalgia patients, supporting regulatory submission for approval
• In January 2024, Tonix Pharmaceuticals reported that the U.S. Food and Drug Administration (FDA) conditionally accepted the trade name “Tonmya” for TNX-102 SL, advancing the product toward commercialization and regulatory approval in the fibromyalgia treatment landscape
• In July 2024, the U.S. FDA granted Fast Track designation to TNX-102 SL, recognizing its potential to address unmet needs in fibromyalgia management and accelerating its regulatory review process
• In March 2025, Tonix Pharmaceuticals announced that the FDA would not require an advisory committee meeting for its New Drug Application (NDA) for TNX-102 SL, indicating a streamlined regulatory pathway and increasing the likelihood of timely approval
• In August 2025, the U.S. FDA approved Tonmya (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia, marking the first new FDA-approved drug for fibromyalgia in over 15 years and introducing a novel non-opioid therapy targeting sleep disturbances associated with the condition
• In December 2025, Tonmya was commercially launched and made available in pharmacies, representing a major commercialization milestone and expanding treatment options for patients suffering from chronic widespread pain, fatigue, and sleep disturbances associated with fibromyalgia

SKU-53653